Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Show More...

  • Website https://www.savarapharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 2.28 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -74.9 -32.9 -23.1 -19.6 -16.1 -9.48 -5.62 -1.76 -1.85 -1.95 -1.88
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 2.0 1.0 2.0 18.0 33.0 40.0 45.0
    Book Value Per Share * USD 120.67 63.3 63.23 36.16 19.86 14.35 3.62 2.45 3.35 2.1 1.67
    Free Cash Flow Per Share * USD -44.45 -37.12 -20.84 -18.29 -14.8 -13.44 -14.42 -4.12 -1.25 -1.21
    Return on Assets % -75.12 -29.35 -28.59 -42.03 -45.65 -63.89 -100.08 -34.67 -39.44 -54.19 -60.75
    Financial Leverage (Average) 1.07 1.09 1.12 1.16 1.2 2.27 1.84 1.34 1.41 1.34 1.37
    Return on Equity % -84.48 -31.77 -31.57 -47.95 -53.92 -96.53 -214.57 -47.69 -54.07 -74.48 -86.17
    Return on Invested Capital % -84.84 -31.93 -31.72 -48.08 -54.05 -70.28 -130.99 -40.13 -46.0 -60.12 -68.03
    Interest Coverage -65.07 -17.06 -27.8
    Current Ratio 15.77 20.98 14.46 9.42 6.92 1.82 2.5 16.27 15.63 11.4 13.9
    Quick Ratio 15.53 20.54 14.21 9.18 6.79 1.77 2.32 15.85 15.51 11.34 13.79
    Debt/Equity 0.16 0.24 0.13 0.23 0.23 0.28